Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S, Jacobus TL, Konen FF, Hümmert MW, Sühs KW, Schwenkenbecher P, Ahlbrecht J, Möhn N, Müschen LH, Bönig L, Alvermann S, Schmidt RE, Stangel M, Jacobs R, Skripuletz T. Gingele S, et al. Among authors: alvermann s. Cells. 2018 Dec 28;8(1):12. doi: 10.3390/cells8010012. Cells. 2018. PMID: 30597851 Free PMC article.
Immunophenotyping of cerebrospinal fluid cells by Chipcytometry.
Hümmert MW, Alvermann S, Gingele S, Gross CC, Wiendl H, Mirenska A, Hennig C, Stangel M. Hümmert MW, et al. Among authors: alvermann s. J Neuroinflammation. 2018 May 25;15(1):160. doi: 10.1186/s12974-018-1176-7. J Neuroinflammation. 2018. PMID: 29801453 Free PMC article.
Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen.
Gingele S, Hümmert MW, Alvermann S, Jendretzky KF, Bönig L, Brieskorn M, Schwenkenbecher P, Sühs KW, Müschen LH, Osmanovic A, Schreiber-Katz O, Stangel M, Petri S, Skripuletz T. Gingele S, et al. Among authors: alvermann s. Front Neurol. 2019 Jul 11;10:735. doi: 10.3389/fneur.2019.00735. eCollection 2019. Front Neurol. 2019. PMID: 31354609 Free PMC article.
Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Böselt S, Escher C, Garde N, Gingele S, Kaehler SB, Karatschai R, Krüger THC, Sikorra S, Tacik P, Wegner F, Wollmann J, Bigalke H, Wohlfarth K, Rummel A. Kutschenko A, et al. Among authors: alvermann s. Clin Neurophysiol. 2019 Jun;130(6):1066-1073. doi: 10.1016/j.clinph.2019.02.007. Epub 2019 Feb 28. Clin Neurophysiol. 2019. PMID: 30871800
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.